Table 2 Main adverse effects by treatment group.
Toxicities | R-M (n = 184 cycles) | R-MA (n = 39 cycles) cecs) | p value |
|---|---|---|---|
Grade 3 neutropenia | 3(1.6%) | 6(15.4%) | 0.001 |
Grade 4 neutropenia | 2(1.1%) | 17(43.6%) | < 0.001 |
Grade 3 thrombopenia | 4(2.2%) | 3(7.7%) | 0.10 |
Grade 4 thrombopenia | 2(1.1%) | 20(51.3%) | < 0.001 |
Grade 3 anemia | 1(0.5%) | 5(12.8%) | 0.001 |
Grade 4 anemia | 0(0%) | 4(10.3%) | 0.001 |
Febrile neutropenia | 5(2.7%) | 16(41.0%) | < 0.001 |
Urinary tract infection | 3(1.6%) | 7(17.9%) | < 0.001 |
Pneumonia | 3(1.6%) | 7(17.9%) | < 0.001 |
Oral candidiasis | 3(1.6%) | 0(0%) | 1.00 |
Sepsis | 1(0.5%) | 1(2.6%) | 0.32 |
Acute infectious enteritis | 1(0.5%) | 0(0%) | 1.00 |
Herpes zoster | 1(0.5%) | 0(0%) | 1.00 |
Grade 3 Hepatotoxicity | 3(1.6%) | 3(7.7%) | 0.068 |
Grade 4 Hepatotoxicity | 1(0.5%) | 0(0%) | 1.00 |
Creatinine elevated | 2(1.1%) | 0(0%) | 1.00 |
Deep vein thrombosis | 0(0%) | 1(2.6%) | 0.18 |
Atrial fibrillation | 0(0%) | 2(5.1%) | 0.03 |
Acute heart failure | 0(0%) | 1(2.6%) | 0.18 |
Grade 4 skin rash | 0(0%) | 1(2.6%) | 0.18 |
